AIDS and HIV Infections

Group leader: José Antonio Iribarren, M.D., Ph.D.

Donostialdea IHO joseantonio.iribarrenloyarte@osakidetza.eus

Strategic Objectives

To improve our patients’ care through applied clinical research in a sustainable framework.

Lines of research

  • HIV:
    • Effectiveness and efficiency of antiretroviral treatment (efficiency, virologic failure, etc.).
    • New care arrangements.
    • Cohort morbidity and mortality.
    • Access to clinical trials.
  • HIV/HVC co-infection:

    • Natural history in the age of TAR.
    • Alternatives to biopsy
    • Effectiveness of treatments.
    • Access to clinical trials.
  • Non-HIV infections:
    • Infective endocarditis.
    • Prosthetic joint infection and other infections of the musculoskeletal system.
    • Access to clinical trials (Clostridium difficile, cellulitis and other organ infections).

Team Members

Name Surname
Center E-mail
Harkaitz Azkune Galparsoro Donostialdea IHO  
Maria Jesús Bustinduy Odriozola Donostialdea IHO majesus.bustinduyodriozola@osakidetza.eus
Xabier Camino Ortiz De Barrón Donostialdea IHO xabier.caminoortizdebarron@osakidetza.eus
Miguel Angel Goenaga Sánchez Donostialdea IHO miguelangel.goenagasanchez@osakidetza.eus
Maialen Ibarguren Pinilla Donostialdea IHO maialen.ibargurenpinilla@osakidetza.eus
Xabier Kortajarena Urkola Donostialdea IHO xabier.kortajarenaurkola@osakidetza.eus
Aitziber Lizardi Mutuberria Donostialdea IHO  aitziber.lizardimutuberria@osakidetza.eus
Francisco Rodríguez Arrondo Donostialdea IHO francisco.rodriguezarrondo@osakidetza.eus
Miguel Angel Von Wichmann De Miguel Donostialdea IHO miguelangel.vonwichmanndemiguel@osakidetza.eus

Scientific Output

Originals

Published: 10 / 116

Dolutegravir plus Abacavir-Lamivudine for the Treatment of HIV-1 Infection.

Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutierrez F, Hocqueloux L, Maggiolo F, Sandkovsky U, Granier C, Pappa K, Wynne B, Min S, Nichols G, SINGLE Investigators.

N. Engl. J. Med. 2013; 369: 1807-1818. FI: 51.658 (Q1).

Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial.

Arribas JR, Girard PM, Landman R, Pich J, Mallolas J, Martinez-Rebollar M, Zamora FX, Estrada V, Crespo M, Podzamczer D, Portilla J, Dronda F, Iribarren JA, Domingo P, Pulido F, Montero M, Knobel H, Cabie A, Weiss L, Gatell JM, OLE RIS-EST13 Study Grp.

Lancet Infect. Dis. 2015; 15: 785-792. FI: 22.433 (Q1).

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.

Raffi F, Jaeger H, Quiros-Roldan E, Albrecht H, Belonosova E, Gatell JM, Baril JG, Domingo P, Brennan C, Almond S, Min S, Extended SPRING-2 Study Grp.

Lancet Infect. Dis. 2013; 13: 927-935. FI: 19.966 (Q1).

Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials.

Eron JJ, Cooper DA, Steigbigel RT, Clotet B, Gatell JM, Kumar PN, Rockstroh JK, Schechter M, Markowitz M, Yeni P, Loutfy MR, Lazzarin A, Lennox JL, Strohmaier KM, Wan H, Barnard Richard JO, Nguyen BYT, Teppler H, BENCHMRK Study Teams.

Lancet Infect. Dis. 2013; 13: 587-596. FI: 19.966 (Q1).

Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study.

Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L, D:A:D study group, Royal Free Hospital Clinic Cohort, INSIGHT study group, SMART study group, ESPRIT study group.

PLoS Med. 2015; 12. FI: 14.429 (Q1).

Hepatic steatosis and steatohepatitis in human immunodeficiency virus/hepatitis C virus-coinfected patients.

Macías J, Berenguer J, Japón MA, Giron-González JA, Rivero A, López-Cortés LF, Moreno A, Márquez M, Iribarren JA, Ortega E, Miralles P, Merchante N, Pineda JA.

Hepatology. 2012; 56: 1261-1270. FI: 11.665 (Q1).

Predicting Survival of HIV-Infected Patients with Liver Cancer – the SHILCA Score and Staging Model.

Chen TY, Merchante N, Citti CC, Platt HL, Badshah MB, Ventura-Cots M, Merino E, Kikuchi L, Jain MK, Rodriguez-Arrondo F, Minguez B, Yin M, Aytaman A, Tural C, Schwartz M, Dieterich D, Aberg J, Pineda J, Marrero JA, Sherman M, Hoshida Y, Braeu N.

Hepatology. 2014; 60: 835-0. FI: 11.190 (Q1).

Low Risk of Liver Decompensation Among Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients With Mild Fibrosis in the Short Term.

Macias J, Mancebo M, Marquez M, Merino D, Tellez F, Rivero A, Von Wichmann, MA, Lopez-Cortes, LF, Merchante N, Santos J, Raffo M, Perez-Perez M, Camacho A, Iribarren JA, Pineda JA.

Hepatology. 2015; 61: 1503-1511. FI: 11.055 (Q1).

Clinical effects of viral relapse after interferon plus ribavirin in patients co-infected with human immunodeficiency virus and hepatitis C virus.

Berenguer J, Alvarez-Pellicer J, Carrero A, Von Wichmann MA, Lopez-Aldeguer J, Mallolas J, Galindo MJ, Van den Eynde E, Tellez MJ, Quereda C, Tural C, Sanz J, Barros C, Santos I, Pulido F, Guardiola JM, Ortega E, Rubio R, Jusdado JJ, Montes ML, Gaspar G, Barquilla E, Bellon JM, Gonzalez-Garcia J, GESIDA HIV HCV Cohort Study Grp.

J. Hepatol. 2013; 58: 1104-1112. FI: 9.858 (Q1).

Risk of Liver Decompensation Among HIV/Hepatitis C Virus-Coinfected Individuals With Advanced Fibrosis: Implications for the Timing of Therapy.

Macias J, Marquez M, Tellez F, Merino D, Jimenez-Aguilar P, Lopez-Cortes LF, Ortega E, von Wichmann MA, Rivero A, Mancebo M, Santos J, Perez-Perez M, Suarez-Lozano I, Romero-Palacios A, Torres-Cornejo A, Pineda JA.

Clin. Infect. Dis. 2013; 57: 1401-1408. FI: 9.374 (Q1).

Reviews

Published: 2 / 2

Characteristics and Outcome of Streptococcus pneumoniae Endocarditis in the XXI Century: A Systematic Review of 111 Cases (2000-2013).

de Egea V, Muñoz P, Valerio M, de Alarcón A, Lepe JA, Miró JM, Gálvez-Acebal J, García-Pavía P, Navas E, Goenaga MA, Fariñas MC, Vázquez EG, Marín M, Bouza E, GAMES Study Group.

Medicine (Baltimore). 2015; 94. FI: 5.723 (Q1).

Clinical Response to Thalidomide in the Treatment of Intracranial Tuberculomas: Case Report.

de la Riva P, Urtasun M, Castillo-Trivino T, Camino X, Arruti M, Mondragon E, Lopez de Munain A.

Clin. Neuropharmacol. 2013; 36: 70-72. FI: 1.815 (Q3).

Editorials

Published: 1 / 1

Nodular skin lesions in a patient from Nicaragua.

Perez N, Jaka A, de la Caba I, Goenaga MA.

Enferm. Infecc. Microbiol. Clin. 2013; 31: 114-115. FI: 1.478 (Q4).

Letters

Published: 10 / 10

Rare LEDGF/p75 genetic variants in white long-term nonprogressor HIV plus individuals.

Ballana E, Gonzalo E, Grau E, Iribarren JA, Clotet B, Este JA

Aids. 2012; 26: 527-528. FI: 6.245 (Q1).

Emergence of resistance to daptomycin in a cohort of patients with methicillin-resistant Staphylococcus aureus persistent bacteraemia treated with daptomycin.

Gasch O, Camoez M, Dominguez MA, Padilla B, Pintado V, Almirante B, Martin C, Lopez-Medrano F, Ruiz de Gopegui E, Blanco JR, Garcia-Pardo G, Calbo E, Montero M, Granados A, Jover A, Duenas C, Pujol M. REIPI Study Grp, GEIH Study Grp.

J. Antimicrob. Chemother. 2014; 69: 568-571. FI: 5.439 (Q1).

Outpatient parenteral antimicrobial therapy (OPAT) for infectious endocarditis in Spain.

Goenaga MA, Kortajarena X, Ibarguren O, Garcia R, Bustinduy MJ, Azkune H, GAMEGI Grp.

Int J Antimicrob Agents. 2014; 44: 89-90. FI: 4.259 (Q1).

TACI mutation in Good’s Syndrome: In search of a genetic basis.

Sáenz-Cuesta M, Martínez-Pomar N, De Gracía J, Echaniz P, Villegas E, Prada A, Otaegui D, Matamoros N, Cuadrado E.

Clin. Immunol. 2012; 145: 27-30. FI: 4.046 (Q2).

Endocarditis due to Streptococcus tigurinus: presentation of a case and a review of the literature.

Michelena A, Bonavila C, Zubeltzu B, Goenaga MA.

Enferm. Infec. Microbiol. Clin. 2015; 33: 575-576. FI: 2.172 (Q3).

Decree on biobanks.

Goenaga-Sánchez A, Royal M.

Enferm. Infec. Microbiol. Clin. 2012; 30: 277-0. FI: 1.491 (Q3).

Home parenteral antibiotic treatment in infectious endocarditis. Current situation.

Goenaga MA, Gamegi Grupo.

Enferm. Infecc. Microbiol. Clin. 2013; 31: 272-273. FI: 1.478 (Q4).

Características de los pacientes con infección por el virus de la inmunodeficiencia humana que no reciben tratamiento antirretroviral en España: estudio PICNIT.

Domingo P, Viciana P, Castaño M, Ferrer E.

Med. Clin. 2015; 144: 43-44. FI: 1.417 (Q2).

Current neurological mortality rates in infectious endocarditis.

De la Riva P, de Arce Borda AM, Diez N, Goenaga MA.

Neurologia. 2014; 29: 312-313. FI: 1.289 (Q4).

Endocarditis infecciosa por Listeria monocytogenes a propósito de dos nuevos casos con mala evolución clínica.

Fuertes A, Goenaga MÁ, Ibarguren M, Pérez N, Elola M.

Rev. Esp. Quim. 2012; 25: 169-170. FI: 0.810 (Q4).

Others

Published: 2 / 2

Perfil de seguridad de rilpivirina: tolerabilidad general y neuropsiquiátrica, seguridad en pacientes coinfectados con virus de la hepatitis B/virus de la hepatitis C, y perfil lipídico.

Lopez LF, Martinez E, von Wichmann MA.

Enferm. Infecc. Microbiol. Clin. 2013; 31 (2): 6-11. FI: 1.478 (Q4).

Validación y cumplimentación de los indicadores de calidad GESIDA en pacientes con infección por el VIH.

Riera M, Esteban H, Suarez I, Palacios R, Lozano F, Blanco JR, Valencia E, Ocampo A, Amador C, Frontera G, GESIDA Study Group of the HIV quality indicators, GESIDA Study Group of the HIV quality indicators.

Enfermedades Infecciosas Y Microbiologia Clinica. 2016; 34: 346-352. FI: 1,714 (Q3).

Projects

Projects 1 / 1

Periodicidad de consulta y efectividad del tratamiento en pacientes con infección por VIH en tratamiento antirretroviral con buen control virológico un ensayo clínico aleatorizado.

Investigador Principal: José Antonio Iribarren Loyarte. Entidad Financiadora: Departamento de Sanidad. Año inicio: 2009. Año final: 2012.